-
公开(公告)号：US20220218867A1
公开(公告)日：2022-07-14
申请号：US17608706
申请日：2020-05-20
摘要： Naturally-derived biopolymers, such as proteins and polysaccharides are a promising platform for developing materials that readily adhere to tissues upon chemical crosslinking and provide a regenerative microenvironment. Here, we show that the sealing properties of a model biopolymer sealant, gelatin methacryloyl (GelMA), can be precisely controlled by adding a small amount of a synthetic polymer with identically reactive moieties, i.e., poly (ethylene glycol) diacrylate (PEG DA). For example, we have discovered a more than 300% improvement in tissue sealing capability of 20% (w/v) GelMA adhesive can be obtained by adding only 2-3% (v/v) PEGDA, without any significant effect on the sealant degradation time scale. These hybrid hydrogels with improved sealing properties are suitable for sealing stretchable organs, such as bladder, as well as for the anastomosis of tubular tissues/organs.
-
公开(公告)号：US20210386985A1
公开(公告)日：2021-12-16
申请号：US17286443
申请日：2019-10-28
发明人： Alireza Khademhosseini , Wujin Sun
摘要： A microneedle patch is described that can be used for the sustained delivery of therapeutic agents into living tissue (e.g., skin). The polymer (gelatin methacryloyl (GelMA)) patch can adjust delivery rates based on the degree of crosslinking. The anticancer drug Doxorubicin (DOX) was loaded into GelMA microneedles using a molding fabrication technique. The GelMA microneedles efficiently penetrated the stratum corneum layer of a mouse cadaver skin. Mechanical properties and therapeutic agent release behavior of the GelMA microneedles can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA microneedles was tested and demonstrated the anticancer efficacy of the released drugs against melanoma cell line A375. Because GelMA is versatile material in engineering tissue scaffolds, GelMA microneedles can be used as a platform for the delivery of various types of therapeutic agents to tissue.
-
公开(公告)号：US20210403649A1
公开(公告)日：2021-12-30
申请号：US17279283
申请日：2019-10-18
摘要： Despite the significant advances in designing injectable bulk hydrogels, the inability to control the pore interconnectivity and decoupling it from the matrix stiffness has tremendously limited the applicability of stiff, flowable hydrogels for 3D cellular engineering. To address this problem, we developed a universal method to convert macromolecules and the like with orthogonal chemical and/or physical responsivity, e.g., thermosensitive macromolecules with chemically-crosslinkable moieties, into annealable building blocks, forming 3D microporous beaded scaffolds in a bottom-up approach. For example, gelatin methacryloyl (GelMA), a widely used biomaterial in tissue engineering, may be converted into physically-crosslinked microbeads using a facile microfluidic approach, followed by flow of the microbead slurry and chemical crosslinking in situ to fabricate microporous beaded GelMA (B-GelMA) scaffolds with interconnected pores, promoting cell functionality and rapid (within minutes) 3D seeding in stiff scaffolds, which are otherwise impossible in the bulk gel counterparts.
-
公开(公告)号：US20230015942A1
公开(公告)日：2023-01-19
申请号：US17783265
申请日：2020-12-10
发明人： KangJu Lee , Alireza Khademhosseini
摘要： A delivery device or patch is disclosed that includes a detachable hybrid microneedle depot (d-HMND) for cell delivery. The system includes, in one embodiment, an array of microneedles formed from an outer PLGA shell and an internal gelatin methacryloyl (GelMA)-mesenchymal stem cells (MSC) mixture (GMM). The array of microneedles project from a base substrate layer that may be flexible. The therapeutic device may be applied to a tissue site of interest and the base substrate layer is removed leaving the hybrid microneedles in the tissue at the site of application to deliver MSCs. Other stem/therapeutic cells may also be delivered with the hybrid microneedles.
-
公开(公告)号：US20190177677A1
公开(公告)日：2019-06-13
申请号：US16324535
申请日：2017-08-19
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , BRIGHAM AND WOMEN'S HOSPITAL
摘要： A microfluidic device for processing cells for the intracellular delivery of molecules or other cargo includes a plurality of microchannels disposed in a substrate or chip and fluidically coupled to an inlet configured to receive a solution containing the cells and the molecules or other cargo to be delivered intracellularly to the cells. Each of the plurality of microchannels has one or more constriction regions therein, wherein the constriction regions comprise an omniphobic, superhydrophilic, or superhydrophobic surface. In some embodiments, multiple microfluidic devices operating in parallel are used to process large numbers of cells. The device and method has particularly applicability to delivering gene-editing molecules intracellularly to cells.
-
公开(公告)号：US20220378975A1
公开(公告)日：2022-12-01
申请号：US17772399
申请日：2020-11-18
摘要： The invention provides injectable, tough hydrogels that can be crosslinked in situ on demand using minimally-invasive methods, such as visible light exposure is an unmet medical challenge. Among the emerging biopolymers for tissue sealing, gelatin methacryloyl (GelMA), a naturally-derived biopolymer obtained from denatured collagen, has secured a promising role as a result of its excellent bioadhesion, biodegradation, and biocompatibility. To overcome one of the main shortcomings of GelMA, i.e., brittleness, we hybridized it using methacrylate-modified alginate (AlgMA) to impart ion-induced reversible crosslinking that can dissipate energy under strain. The hybrid GelMA-AlgMA hydrogels provide a photocrosslinkable, injectable, and adhesive platform with an excellent toughness that can be engineered using divalent cations, such as calcium. This class of novel hybrid biopolymers with more than 600% improved toughness may set the stage for durable, mechanically-resilient, and cost-effective tissue sealants in minimally invasive procedure, especially for stretchable tissues.
-
公开(公告)号：US20220361876A1
公开(公告)日：2022-11-17
申请号：US17769686
申请日：2020-10-15
IPC分类号： A61B17/08
摘要： The present invention relates to bio-zipper surgical closure devices configured to provide tension-free support of an incision throughout the healing process. Further, the present invention provides a surgical closure device to be used for urethral tubular closure during a urethroplasty. The present invention relates to methods of using the surgical closure device for the closure of various wounds such as urethral tubular closure during a urethroplasty.
-
公开(公告)号：US20220080376A1
公开(公告)日：2022-03-17
申请号：US17425027
申请日：2020-02-18
IPC分类号： B01J13/00
摘要： Converting colloidal systems, such as emulsions, dispersions, and suspensions to powders is highly demanded in a myriad of biomedical, pharmaceutical, cosmetic, oil and gas, food, energy, and environmental applications. Handling colloids is typically associated with persistent challenges including bacterial and viral contaminations, lack of terminal sterilization, impaired stability, short shelf life, high processing costs, and difficult packaging and transportation. Current techniques such as freeze-drying and spray-drying have noticeably failed in completely preserving the properties of dispersed phase while removing the continuous phase. The invention disclosed herein provides a new and easy method to convert colloidal systems to powders that are able to readily revive their properties upon resuspension.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)